A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

Inclusion Criteria

• •Donor:
• •Donor eligibility will be determined according to applicable federal, state and local regulations and institutional standards
• •18-65 years of age
• •6/6 HLA-matched sibling
• •Fulfill individual Transplant Center criteria to serve as a mobilized blood cell donor
• •Serum creatinine \<2.0mg/dl
• •Recipient:
• •18 to 65 years of age
• •6/6 HLA antigen matched sibling willing to donate PBSC for transplant
• •Fulfill individual Transplant Center Criteria for transplant
• •One of the following diagnoses:
• •* Acute myelogenous leukemia (AML) in 1st remission or beyond with \<5% marrow blasts and no circulating blasts. Marrow must be done within 30 days of the start of transplant conditioning regimen in alignment with other pre-transplant assessments.
• •* Acute lymphoblastic leukemia (ALL) in 1st remission or beyond with \<5% marrow blasts and no circulating blasts
• •* Myelodysplastic syndrome, either intermediate-1,2, or high risk by International Prognostic Scoring System or transfusion dependent
• •* Chronic myelogenous leukemia (CML) failing or intolerant to tyrosine kinase inhibitor based therapy
• •* Non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) in 2nd or greater complete remission, partial remission, or in relapse (but with at least stable disease after most recent therapy)
• •* Chronic lymphocytic leukemia (CLL), relapsing after at least one prior regimen, or in remission with 17p deletion
• •Serum creatinine must be \<2.0mg/dl
• •Total bilirubin and aspartate aminotransferase (AST) \<3x normal
• •Infectious disease marker (IDM) monitoring will be performed per institutional standards
• •Karnofsky performance status of 70% or greater.
• •Patients who have undergone a prior autologous transplantation are eligible for a reduced intensity transplant only